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Abstract 
 
PGV-0 is a synthetic compound which is modified compound from curcumin. This compound whould be 
expected to be a new drug, since this substance has a potent inflammatory effect with a very low  toxicity. 
However, this substance has poor biopharmaceutic properties, it means that this compound is practically 
insoluble in water. It has been reported, that the solubility of PGV-0 was increasd by presence of PVP. So 
the aims of this study was to know the effect of PVP to the in vitro intestinal absorption of  PGV-0 on 
rats. It was evident that the PGV-0 absorption was increased significantly by PVP addition, but there was 
not any effect on the lag time of the in vitro intestinal absorption.           
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Introduction 
 
A number of active compounds of drgs are 
pooly soluble in the aqueous fluid of gastrointestinal 
tract. Consequently, the in vivo dissolution rate of 
these compounds are low, and the gastrointestinal 
absorption tend to be incomplete. 
Pentagamavunon-0 (PGV-0) is a curcumin 
derivate, a synthetic compound that would be 
expected to be a new drug. This substance has potent 
anti-inflammatory effect with a very low toxicity. 
However, this compound is practically insoluble in 
water, so the  gastrointestinal absorption will be 
limited gy dissolution. By improving its solubility 
would be increased its dissolution rate and the 
bioavailability as well. The correlation between the 
solubility of substance and its dissolution rate 
follows the Fick’s first law equation as follows 
(Martin, et al., 1993) 
 
dC/dt  =   D A/V h   x   (Cs  -  Cb)  (1) 
 
where, dC/dt = the dissolutionrate; A = surface area; 
V = volume of dissolution medium; h = the 
thickness of the diffusion layer, Cs  =  solubility and 
Cb  = the concentration of diffusant or the 
concentration og diffusant attime, t. 
Wahyuningsih (2004) had proved that the 
solubility of  PGV-0 was increased with presence of 
polyvinylpyrrolidone (PVP). This substance is 
pharmacologically inactive and non- 
 
toxic. In industrial pharmacy. PVP is used as the the 
formulation exipience, for instant can be used as the 
fastner at tablet formulation (Anonim, 1986). Some 
opinions concider that crustal growth will be hindered 
by PVP, and it can be used as adjuvant at the preparing 
the solid dispersion of the poor solubility of drug, it 
means to increase it dissolution behavior (Chiuou and 
Riegelman, 1971; Akbuga et al., 1988). 
The main point of this study was to know, the 
effect of PVP to the in vitro intestinalabsorption of 
PGV-0,  and the effect to the lag time at its diffusion 
process. The everted small intestinal sac technique was 
used at this study, and carried out with the modification 
of Crane and Wilson apparatus (Bates and Gibaldi, 
1070).  
The mass transfer through the intestine membrane 
relating to the lag time follows the equation (Martin el 
al., 1993): 
 
M   =    D A K Cd/ h     (t – tL)   (2) 
 
Where, M =  the amount of diffusant has be transferred 
at the time t; D = the diffusity in intestinal membrane, 
A = the area of the membrane; K = the partition 
coefficient between membrane and aqueous medium in 
the intestine; Cd = the concentration of the diffusant; h 
= the membrane thickness;  and tL = lag time, and 
 
tL   =    h2/6D    (3) 
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Methodology 
 
The main material applied to this study was 
pentagamavunon-0 (2,5-bis{4’-hydroxy-3-
methoxybenzelidene} cyclopentanone), obtained 
from MOLNAS Faculty of Pharmacy, Gadjah Mada 
University. The other chemicals were: PVP 25 p.a. 
(E Merck), albumin p.a. (E Merck), Sodium chloride 
p.a. (E Merck), and the other chemical were 
pharmaceutical grade, and the test animals were 
male rats (Wistar) 
The male rats were fasted for a period of 20 
to 24 hours. Water was allowed ad libitum. The 
animals were killed by anesthetized with ether. The 
abdominal region were exposed by mean of a 
midline incision. The entire small intestine were 
excised, and the rats was sacrificed, if necessary.The 
lumen were flushed immediately with cold normal 
saline (physiologic sodium chloride solution), and 
the distal portion (10 to 15 cm from the pylorus) is 
cut and discarded to prevent inclusion of the 
entrance of the bile duct in the test segment. The 
next step was to evert the entire small intestine with 
a smooth glass (Bates and Gibaldi, 1970). 
The distal end of 7 cm jejunum segment 
was tied, and the proximal end attached to the 
cannula. The segment was suspended in a 
predetermined volume (75 ml) of mucosal solution 
which containing of saturated PGV-0 as mucosal 
solution at 370 + 0,50 C. The cannula was adjusted 
to immerse the sac completely.  A small volume (1.4 
ml) of drug-free physiologic sodium chloride 
solution was then placed the serosal compartment. 
The mucosal solution was continually gassed with 
carbogen 100 bubbles per minutes (Bates and 
Gibaldi, 1970). 
For determining the rate of PGV-0 transfer 
across the intestine, the entire volume of serosal 
solution was removed from the sac at each time 
interval, then the concentration of PGV-0 was 
assayed spectrophotometrically. A fresh physiologic 
sodium chloride solution was finally added to the 
sac, to serve as the serosal fluid for next-time 
period. At conclusion of the experiment, the gut may 
be assayed for accumulated PGV-0.  
 
 
Results and Dicussions 
  
The first step of this study was making 
orientation by using varying concentrations of PGV-
0 and PVP solution as the mucosal solution and the 
normal saline as the serosal solution. After 75 
minutes incubation, the concentration of PGV-0 
which had been transferred to the serosal solution 
was assayed spectrophotometrically. The results were 
undetectable PGV-0, because the concentration of 
PGV-0 were very low.  
The absence of in vitro absorption in this trial 
was may be because of the difference the serosal 
solution used in this trial  witch physiological solution. 
In the body, drugs are distributed through out the body 
by blood. Albumin is the main component of blood 
protein which bind most of the drug, while the other 
protein have less role in drug binding (Shargel et al., 
2005). So the next step was a trial for the orientation by 
adding albumin to the serosal solution. 
From that trial, absorption was finally 
detected when serosal solution contained albumin. 
Based on that, for the next trial were used mucosal 
solution consisted of 5 mg % PGV-0 in physiologic 
sodium chloride with 2 % PVP. For the serosal 
solution, were used 1 % albumin in the physiologic 
sodium chloride and the concentration of PGV-0 were 
assayed after  90, 180 and 270 minutes incubation. 
In this in vitro absorption trial, would be 
observed the influence of PVP to the amount of PGV-0 
transported through jejunum or ileum. In this study, 
saturated solution of PGV-0  in physiologic sodium 
chloride solutions with and without PVP were used as 
mucosal solution. The pertinent value for the jejunum 
trial were given in Table I. 
 
Table I.  The amount of cumulative of PGV-0 which 
is transported through jejenum from 
saturated solution PGV-0 and mixture 
PGV-0 - PVP from mucosal solution to 
serosal solution in vitro. 
 
No. 
The amount of cumulative of PGV-0 which is transported  in jejunum 
90 (Minute) 180 (Minute) 270(Minute) 
PGV-0 
solution
PGV-0 – 
PVP 
solution 
PGV-0 
solution 
PGV-0 – 
PVP 
solution 
PGV-0 
solution 
PGV-0 
– PVP 
solution 
1 0,0003* 0,0034* 0,0029
* 0,0144 0,0029* 0,0144 
2 0,0004* 0,0018* 0,0028
* 0,0148 0,0028* 0,0148 
3 0,0005* 0,0014* 0,0033
* 0,0214 0,0033* 0,0214 
4 0,0005* 0,0027* 0,0039
* 0,0236 0,0039* 0,0236 
5 0,0005* 0,0035* 0,0027
* 0,0168 0,0027* 0,0168 
Mean 0,0005 0,0027 0,0031 0,0182 0,0031 0,0182 
Description : * = calculation result of extrapolation  
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For analyze the effect of PVP to the amount 
of PGV-0 transported through jejunum, was done by 
Paired t-test in SPSS with P <  0,05. It means that 
PVP could increase transported PGV-0 through 
jejunum. This data support the estimation that PVP 
could increase PGV-0 absorption by increasing 
PGV-0 solubility. 
From table I, the linear regression was 
made. The amount of transported PGV-0 was used 
as time function to calculate the lag time. From each 
linear equation, can be calculated the intersection 
according to the x-axis to determine the lag time 
value, as seen to the table II. 
 
Table  II.  The lag time PGV-0 at jejunum by 
using mukosal  solution  without PVP 
and also with PVP. 
 
No. 
Lag time PGV-0 at 
jejunum without PVP 
(minute) 
Lag time PGV-0 at 
jejunum with PVP 
(minute) 
1 69,67 51,22 
2 58,33 70,91 
3 62,14 72,89 
4 68,75 70,67 
5 57,14 55,70 
 x  = 63,21 SD = 5,18 x  = 64,28 SD = 8,98   
 
Paired t-test analysis between lag time 
PGV-0 in jejunum not using and using PVP shows 
meaningless difference (P  >   0.5), which mean, that 
PVP addition did not change the PGV-0 lag time in 
jejunum.  It may be because of the fact that , even 
PVP can increase the absorption of PGV-0 by 
complex formation PVP-PGV-0, but the free PGV-0 
the only capable to pass the membrane. 
The amount of transported PGV-0 through 
ileum, using saturated solution of PGV-0 in the 
physiologic sodium chloride, with or without PVP as 
the mucosal solution, can be seen in table III. 
 
Analog the effect of PVP to the in vitro 
absorption of PGV-0 through jejunum, the effect 
through ileum given the same result. Using Paired 
analysis t-test shows that PVP could improve the 
absorption of PGV-0 through ileum significantly (P 
< 0.05), and PVP was not influent to the lag time at 
the ileum absorption process of PGV-0 (P > 0.05), 
as seen to the table IV. 
 
 
 
Table III. The amount of cumulative of PGV-0 which 
is transported through ileum from saturated 
solution PGV-0 and of mixture PGV-0 - 
PVP from mucosal solution  to  serosal 
solution in vitro. 
 
No. 
The amount of cumulative of PGV-0 which is transported  in ileum 
90(minute) 180(minute) 270(minute) 
PGV-0 
solution 
PGV-0 
– PVP 
solution 
PGV-0 
solution 
PGV-0 
– PVP 
solution 
PGV-0 
solution 
PGV-0 
– PVP 
solution 
1 0,0003* 0,0011* 0,0010* 0,0056 0,0029* 0,0144 
2 0,0003* 0,0021* 0,0011* 0,0063 0,0028* 0,0148 
3 0,0004* 0,0024* 0,0011* 0,0095 0,0033* 0,0214 
4 0,0005* 0,0030* 0,0013* 0,0114 0,0039* 0,0236 
5 0,0004* 0,0017* 0,0009* 0,0074 0,0027* 0,0168 
Mean 0,0004 0,0021 0,0011 0,0080 0,0031 0,0182 
 
Description : * = Calculation result of extrapolation 
 
 
Tables IV. The lag time PGV-0 at ileum by using 
mucosal solution without PVP and also 
with PVP. 
  
No. Lag time PGV-0 at ileum without PVP ( minute) 
Lag time PGV-0 at ileum with 
PVP ( minute) 
1 85,71 85,14 
2 78,57 70,42 
3 81,25 66,67 
4 78,95 71,82 
5 73,85 77,38 
 x  = 78,70 ±  SD = 4,14 x  = 74.80 ±  SD = 5.98  
 
 
 
 
The PGV-0 lag time in jejunum and ileum 
were both more than 15 minutes. This such drug 
material usually generates absorption problem through 
the biomembrane. From slope curve at the figure 1, 
seen that the absorption rate of PGV-0 through  
jejunum was faster than through ileum.   
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Fig 1.   The amounts of cumulative of PGV-0 
which is transported at jejunum and ileum 
applies mucosal solution without PVP and 
with PVP 
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Conclusion 
 
1. In this in vitro absorption trials, PVP could 
be enhancer in the absorption of PGV-0 
significantly (P<0.05) either through 
jejunum or ileum atmale rats. 
2. The lag time of PGV-0 transport through 
jejunum or ileum, PVP did not any effect (P 
> 0.05).    
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